← All trials
NCT03109236
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2017
- Primary completion
- Mar 31, 2020
- Completion date
- Mar 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 66
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National University of SingaporeLead sponsor
- National University of SingaporeOverall official - principal investigator
- Singapore General HospitalCollaborator
- Nanyang Technological UniversityCollaborator
- Changi General HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.